28. Sep 2026
Description
(AWP Alliance News) - Merck entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the deal, Merck gains worldwide rights to develop, manufacture, and commercialize the candidate.
SciBrunch will receive an upfront payment of USD 400 million. The agreement includes development and commercialization milestones, lifting the total potential value to USD 2.13 billion.
Merck expects to record a pre-tax charge of USD 400 million in the third quarter of 2026.
https://www.businesswire.com/news/home/20260928125137/en/
Disclaimer: This news brief was created using generative artificial intelligence. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire on September 28, 2026, and is solely responsible for the information contained therein.
